BR112022025134A2 - 5-amino-2,3-dihidro-1,4-ftalazinadiona, composição, combinação, e, método de tratamento de uma infecção coronaviral - Google Patents

5-amino-2,3-dihidro-1,4-ftalazinadiona, composição, combinação, e, método de tratamento de uma infecção coronaviral

Info

Publication number
BR112022025134A2
BR112022025134A2 BR112022025134A BR112022025134A BR112022025134A2 BR 112022025134 A2 BR112022025134 A2 BR 112022025134A2 BR 112022025134 A BR112022025134 A BR 112022025134A BR 112022025134 A BR112022025134 A BR 112022025134A BR 112022025134 A2 BR112022025134 A2 BR 112022025134A2
Authority
BR
Brazil
Prior art keywords
phthalazinedione
treatment
dihydro
amino
composition
Prior art date
Application number
BR112022025134A
Other languages
English (en)
Inventor
Brysch Wolfgang
Kaiser Astrid
Schulz Petra
Schumann Sara
Von Wegerer Jörg
Setz Christian
Schubert Ulrich
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20000366.3A external-priority patent/EP3981405A1/en
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of BR112022025134A2 publication Critical patent/BR112022025134A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

5-AMINO-2,3-DIHIDRO-1,4-FTALAZINADIONA, COMPOSIÇÃO, COMBINAÇÃO, E, MÉTODO DE TRATAMENTO DE UMA INFECÇÃO CORONAVIRAL. O presente pedido refere-se ao uso de uma ftalazinadiona na prevenção ou tratamento de infecções coronavirais. São divulgadas composições farmacêuticas, combinações e técnicas de formulação vantajosas.
BR112022025134A 2020-06-10 2021-06-09 5-amino-2,3-dihidro-1,4-ftalazinadiona, composição, combinação, e, método de tratamento de uma infecção coronaviral BR112022025134A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20000212 2020-06-10
EP20000366.3A EP3981405A1 (en) 2020-10-08 2020-10-08 Compound for the treatment of coronaviral infections
PCT/EP2021/000071 WO2021249667A1 (en) 2020-06-10 2021-06-09 Compound for the treatment of coronaviral infections

Publications (1)

Publication Number Publication Date
BR112022025134A2 true BR112022025134A2 (pt) 2022-12-27

Family

ID=76444360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025134A BR112022025134A2 (pt) 2020-06-10 2021-06-09 5-amino-2,3-dihidro-1,4-ftalazinadiona, composição, combinação, e, método de tratamento de uma infecção coronaviral

Country Status (11)

Country Link
US (1) US20230218614A1 (pt)
EP (1) EP4164651A1 (pt)
JP (1) JP2023529022A (pt)
KR (1) KR20230027150A (pt)
CN (1) CN116075306A (pt)
AU (1) AU2021288757A1 (pt)
BR (1) BR112022025134A2 (pt)
CA (1) CA3182022A1 (pt)
IL (1) IL298899A (pt)
MX (1) MX2022015601A (pt)
WO (1) WO2021249667A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240075029A1 (en) * 2020-12-02 2024-03-07 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
EP4193994A1 (en) * 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
EP4209219A1 (en) * 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
WO2023131579A1 (en) * 2022-01-07 2023-07-13 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
US6953799B1 (en) 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
ITMI20052036A1 (it) 2005-10-26 2007-04-27 Professional Dietetics Srl Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
CA2791327C (en) 2010-03-01 2018-10-30 Metriopharm Ag Crystalline forms of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same, method for production of said forms and use of said forms for modulating the immune system
EP2688565A1 (en) 2011-03-23 2014-01-29 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
JP2017537958A (ja) * 2014-12-18 2017-12-21 メトリオファーム アーゲー ５−アミノ−２，３−ジヒドロフタラジン１，４−ジオンナトリウム塩の結晶形態、同一物を含む医薬製剤、及びこの形態の製造ための方法
CA3011767C (en) 2016-02-16 2024-02-06 Metriopharm Ag Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
ES2796476T3 (es) * 2016-02-16 2020-11-27 Metriopharm Ag Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona
EP3248602A1 (en) * 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
WO2018082814A1 (en) 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
EP4125802A1 (en) * 2020-03-25 2023-02-08 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury
RU2747467C1 (ru) * 2020-07-17 2021-05-05 Муса Тажудинович Абидов Способ защиты от коронавирусной инфекции

Also Published As

Publication number Publication date
CN116075306A (zh) 2023-05-05
EP4164651A1 (en) 2023-04-19
WO2021249667A1 (en) 2021-12-16
MX2022015601A (es) 2023-01-30
US20230218614A1 (en) 2023-07-13
AU2021288757A1 (en) 2023-02-02
IL298899A (en) 2023-02-01
JP2023529022A (ja) 2023-07-06
CA3182022A1 (en) 2021-12-16
KR20230027150A (ko) 2023-02-27

Similar Documents

Publication Publication Date Title
BR112022025134A2 (pt) 5-amino-2,3-dihidro-1,4-ftalazinadiona, composição, combinação, e, método de tratamento de uma infecção coronaviral
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
HRP20050123B8 (hr) Kompozicija i antivirusna aktivnost supstituiranih azaindoloksooctenih piperazin derivata
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
Khalid et al. Identification of oral cavity biofilm forming bacteria and determination of their growth inhibition by Acacia arabica, Tamarix aphylla L. and Melia azedarach L. medicinal plants
NO20064584L (no) Tetrahydropyridoindolderivater
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
BR0015056A (pt) Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico
BR0008912A (pt) Cepas de bactérias do ácido láctico capazes de prevenir a diarréia
WO2009043987A9 (fr) Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales
AU2003241345A1 (en) Use of mastic and its components for the control of microbial infections
RU2012149863A (ru) Полисахарид семени тамаринда для применения в лечении микробных инфекций
BR112022023013A2 (pt) Inibidores de mek para tratamento ou prevenção de infecções por coronavírus e/ou de tempestade de citocinas de covid-19
BR0111678A (pt) Composições medicinais contendo derivados de propenona
BR112019001131A2 (pt) composto virucida, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso dos compostos virucidas
MEP34608A (en) Low concentration of peroxide for treating or preventing vaginal infections
WO2021219244A8 (en) 6'-methoxycinchonan-9-ols for the treatment of coronaviral infections
BR112022006703A2 (pt) Conjugados de interleucina 10 e usos dos mesmos
BR112022004032A2 (pt) Composições probióticas mixotróficas e usos das mesmas no tratamento de distensão abdominal
BR112022007844A2 (pt) Composição antimicrobiana, método não terapêutico de tratamento da pele e/ou cavidade oral de mamíferos e uso não terapêutico de composição
EP4321217A3 (en) Substituted pyridotriazine compounds and uses thereof
BR112023002926A2 (pt) Agentes terapêuticos inaláveis
WO2022079261A3 (en) Use of microorganisms and calcium for improved plant health and/or resilience against plant pathogens